The markets closed mixed with the Dow slipping 12 points to 25,283 ahead of earnings season. Nasdaq gained 20 points to 7157.
On the upside
Novo Nordisk made an unsolicited $3.1 billion offer to acquire Ablynx (Nasdaq: ABLX).
The Food and Drug Administration approved Nevro's (NYSE: NVRO) next generation Senza II Spinal Cord Stimulation System.
Tandem Diabetes Care (Nasdaq: TNDM) successfully completed the first pilot study using a hybrid closed loop system featuring its t:slim X2 Insulin Pump.
On the downside
Oxford Immunotec Global (Nasdaq: OXFD) reported preliminary fourth quarter revenue that fell short of previous guidance.
Natus Medical (Nasdaq: BABY) reported preliminary fourth quarter revenue that was lower than expected.
Invitae (NYSE: NVTA) forecast disappointing 2018 revenue.
In the broad market, advancing issues outpaced decliners by a margin of nearly 3 to 2 on the NYSE while advancers were on par with decliners on Nasdaq. The broader S&P 500 rose 4 points to 2,747. Bitcoin gained $117 to $14,774.